Bicycle Therapeutics PLC Sponsored ADR BCYC
3.69
(0.04)
(1.07%)
as of 25 Sep
- Market cap
- $199.4M
- P/E
- 0.0×
Follow BCYC
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.84 | 5.09 | 6.76 | 18.93 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.97) | (4.90) | (25.35) | (7.54) | |
P/B ratio |
0.58 | 0.58 | 0.80 | 0.87 | |
Price to Tangible BV |
0.58 | 0.58 | 0.80 | 0.87 | |
EV/Sales |
(3.15) | (3.39) | (1.61) | (3.21) | |
EV/EBITDA |
0.94 | 0.91 | 0.48 | 0.32 | |
EV/Operating CF |
0.94 | 0.94 | 0.47 | 0.38 | |
EV/FCF |
0.93 | 0.93 | 0.46 | 0.38 | |
Quick Ratio |
11.70 | 12.28 | 11.65 | 10.33 | |
Current Ratio |
12.08 | 12.66 | 11.98 | 10.66 | |
Net Debt/EBITDA |
9.54 | 8.69 | 26.87 | 10.16 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.09 | 0.08 | 0.09 | 0.03 | |
Operating CF/Net income |
0.99 | 1.08 | 0.96 | 1.20 | |
Capex/Depreciation |
(0.25) | (0.63) | (0.43) | (0.38) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6,543.72% | 5,513.08% | 107.96% | 497.92% | |
Selling, General and Administrative Expense of Revenue |
2,230.21% | 1,969.33% | 43.57% | 160.72% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,018.12% | 781.29% | 24.30% | 74.75% | |
Graham Net Nets |
1.62 | 1.61 | 1.17 | 1.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(64.39%) | (67.89%) | (44.63%) | (46.77%) | |
Free Cash Flow Yield |
(70.37%) | (71.66%) | (51.38%) | (45.09%) | |
Revenue per Share |
0.01 | 0.01 | 0.69 | 0.17 | |
Operating CF per Share |
(0.71) | (0.95) | (0.28) | (1.03) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.71) | (0.96) | (0.29) | (1.04) | |
Cash per Share |
7.31 | 8.03 | 9.07 | 9.35 | |
Shareholders Equity per Share |
7.31 | 7.95 | 8.80 | 8.92 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.31 | 7.95 | 8.80 | 8.92 | |
Free Cash Flow |
(49.87) | (66.64) | (19.92) | (71.85) | |
Working Capital |
527.60 | 570.25 | 625.90 | 669.54 | |
Capital Expenditures |
(0.26) | (0.71) | (0.57) | (0.67) | |
Net Current Asset Value |
478.91 | 521.06 | 575.27 | 593.34 | |
EV/EBIT |
0.92 | 0.89 | 0.47 | 0.31 | |
Capex to Sales |
0.42 | 0.80 | 0.01 | 0.06 | |
Net Profit Margin |
(8,002.07%) | (6,857.38%) | (42.03%) | (503.66%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
54.09 | 43.65 | 35.62 | 62.62 | |
Average Payables |
11.96 | 8.54 | 12.73 | 9.18 | |
Average Assets |
719.38 | 768.15 | 837.23 | 880.35 | |
Average Common Equity |
589.59 | 647.33 | 701.52 | 724.76 |
Columns are period end dates